Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apellis Pharmaceuticals (APLS) Common Equity (2020 - 2025)

Apellis Pharmaceuticals (APLS) has 6 years of Common Equity data on record, last reported at $370.1 million in Q4 2025.

  • For Q4 2025, Common Equity rose 61.96% year-over-year to $370.1 million; the TTM value through Dec 2025 reached $370.1 million, up 61.96%, while the annual FY2025 figure was $370.1 million, 61.96% up from the prior year.
  • Common Equity reached $370.1 million in Q4 2025 per APLS's latest filing, down from $401.2 million in the prior quarter.
  • Across five years, Common Equity topped out at $462.2 million in Q1 2022 and bottomed at -$141.5 million in Q2 2021.
  • Average Common Equity over 5 years is $229.9 million, with a median of $234.7 million recorded in 2023.
  • Peak YoY movement for Common Equity: plummeted 160.97% in 2021, then surged 794.8% in 2022.
  • A 5-year view of Common Equity shows it stood at $198.7 million in 2021, then dropped by 14.49% to $169.9 million in 2022, then rose by 14.51% to $194.5 million in 2023, then increased by 17.49% to $228.5 million in 2024, then skyrocketed by 61.96% to $370.1 million in 2025.
  • Per Business Quant database, its latest 3 readings for Common Equity were $370.1 million in Q4 2025, $401.2 million in Q3 2025, and $156.3 million in Q2 2025.